Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,530 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01926587 | Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine | completed | Phase 1 / Phase 2 | 45 | Traws Pharma, Inc.INDUSTRY | 2 | Jun 16, 2021 | clinicaltrials |
| NCT02190695 | Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS | completed | Phase 2 | 92 | Fox Chase Cancer CenterOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT02500550 |
| completed |
| Phase 2 |
| 15 |
| Kiadis PharmaINDUSTRY |
| 6 |
| May 18, 2021 |
| clinicaltrials |
| NCT04883125 | Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment | completed | Phase 2 | 90 | Mansoura UniversityOTHER | 1 | May 12, 2021 | clinicaltrials |
| NCT03466320 | DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2(DEPLETHINK) | completed | Phase 1 / Phase 2 | 21 | Celyad Oncology SAINDUSTRY | 2 | May 4, 2021 | clinicaltrials |
| NCT02707393 | Allogeneic Stem Cell Transplantation for Children With CML | completed | Phase 2 / Phase 3 | 13 | St. Anna KinderkrebsforschungOTHER | 3 | Apr 15, 2021 | clinicaltrials |
| NCT01361334 | Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible(PAZOPANIB-AML) | completed | Phase 2 | 20 | University Hospital MuensterOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT01961882 | A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia | completed | Phase 2 | 134 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 3 | Mar 26, 2021 | clinicaltrials |
| NCT01338987 | Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation | completed | Phase 2 | 76 | National Cancer Institute (NCI)NIH | 1 | Mar 18, 2021 | clinicaltrials |
| NCT01883362 | Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML(RADIUS) | completed | Phase 2 | 60 | Novartis PharmaceuticalsINDUSTRY | 2 | Mar 17, 2021 | clinicaltrials |
| NCT01216085 | An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints(CML) | completed | Phase 2 | 10 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 10, 2021 | clinicaltrials |
| NCT01736943 | Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia | completed | Phase 2 | 25 | Joseph TuscanoOTHER | 1 | Feb 24, 2021 | clinicaltrials |
| NCT01025778 | Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia | completed | Phase 2 | 7 | Lund University HospitalOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT01912274 | Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 2 | 50 | Helsinn Healthcare SAINDUSTRY | 1 | Feb 9, 2021 | clinicaltrials |
| NCT00637052 | A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia | completed | Phase 1 / Phase 2 | 36 | PfizerINDUSTRY | 1 | Feb 8, 2021 | clinicaltrials |
| NCT00489203 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 140 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT01207440 | Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)(PACE) | completed | Phase 2 | 449 | Ariad PharmaceuticalsINDUSTRY | 11 | Feb 2, 2021 | clinicaltrials |
| NCT01445080 | Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | completed | Phase 1 / Phase 2 | 70 | National Cancer Institute (NCI)NIH | 2 | Feb 2, 2021 | clinicaltrials |
| NCT00469014 | Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia | completed | Phase 2 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT01180322 | Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine(azacitidine) | completed | Phase 2 | 277 | University of UlmOTHER | 2 | Dec 31, 2020 | clinicaltrials |
| NCT01474681 | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies | completed | Phase 1 / Phase 2 | 27 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 30, 2020 | clinicaltrials |
| NCT00831766 | Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 51 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT00067028 | Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML) | completed | Phase 2 | 116 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT00384228 | A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL | completed | Phase 1 / Phase 2 | 42 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT01279473 | Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study) | completed | Phase 1 / Phase 2 | 42 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT02046122 | Adoptive Transfer of Haplo-identical DLI for AML and MDS | completed | Phase 1 / Phase 2 | 19 | Duke UniversityOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT02799147 | GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia | completed | Phase 1 / Phase 2 | 27 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT01914484 | Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia | completed | Phase 1 / Phase 2 | 4 | University Health Network, TorontoOTHER | 1 | Nov 2, 2020 | clinicaltrials |
| NCT03338348 | Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2 | completed | Phase 2 | 9 | University of UlmOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT01816230 | Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM | completed | Phase 1 / Phase 2 | 36 | Gamida Cell ltdINDUSTRY | 5 | Oct 22, 2020 | clinicaltrials |
| NCT02458235 | Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation | completed | Phase 2 | 17 | University of California, San FranciscoOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT02763475 | NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents | completed | Phase 2 | 7 | Instituto de Investigación Hospital Universitario La PazOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT01910012 | PH 2 ADI-PEG 20 Acute Myeloid Leukemia | completed | Phase 2 | 43 | Polaris GroupINDUSTRY | 2 | Oct 1, 2020 | clinicaltrials |
| NCT00309842 | Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases | completed | Phase 2 | 213 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT01274351 | Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) | completed | Phase 2 | 112 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 1, 2020 | clinicaltrials |
| NCT01885897 | IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT | completed | Phase 1 / Phase 2 | 33 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT03820908 | Bisantrene for Relapsed /Refractory AML | completed | Phase 2 | 10 | Sheba Medical CenterOTHER_GOV | 1 | Aug 7, 2020 | clinicaltrials |
| NCT01830361 | Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML(MIDOKIT) | completed | Phase 2 | 18 | Technische Universität DresdenOTHER | 1 | Aug 6, 2020 | clinicaltrials |
| NCT00946647 | A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). | completed | Phase 1 / Phase 2 | 113 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 4, 2020 | clinicaltrials |
| NCT01235572 | Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy | completed | Phase 2 | 200 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT02405338 | DC Vaccination for Post-remission Therapy in AML | completed | Phase 1 / Phase 2 | 20 | Medigene AGINDUSTRY | 1 | Jul 7, 2020 | clinicaltrials |
| NCT01477606 | Protocol in Acute Myeloid Leukemia With FLT3-ITD | completed | Phase 2 | 451 | University of UlmOTHER | 2 | Jun 4, 2020 | clinicaltrials |
| NCT01154816 | Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia | completed | Phase 2 | 118 | Children's Oncology GroupNETWORK | 2 | May 13, 2020 | clinicaltrials |
| NCT01370213 | NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases | completed | Phase 2 | 25 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 13, 2020 | clinicaltrials |
| NCT02560025 | Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML | completed | Phase 2 | 42 | Massachusetts General HospitalOTHER | 1 | May 5, 2020 | clinicaltrials |
| NCT02333058 | Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies | completed | Phase 2 | 70 | medac GmbHINDUSTRY | 6 | May 4, 2020 | clinicaltrials |
| NCT01252667 | Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant | completed | Phase 2 | 44 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 16, 2020 | clinicaltrials |
| NCT02530476 | Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 31, 2020 | clinicaltrials |
| NCT03170895 | Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD | completed | Phase 2 | 5 | The University of Hong KongOTHER | 1 | Mar 30, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jun 16, 2021source: clinicaltrials